Yes, this patient requires maintenance antidepressant therapy despite never having been medicated.
For patients with severe recurrent major depressive disorder who have achieved spontaneous remission, maintenance antidepressant therapy is strongly indicated because the diagnosis of "recurrent" MDD (≥2 episodes) places them at 70% risk of another episode, and this risk increases to 90% after three episodes. 1
Why Medication is Indicated Despite Spontaneous Remission
Your patient's diagnosis of "severe recurrent MDD" is the critical factor here. The American College of Physicians guidelines explicitly state that patients who have had 2 or more episodes of depression require an even longer duration of therapy beyond the standard 4-9 months recommended for first episodes 2. This recommendation applies regardless of whether the current remission was achieved with or without medication.
Key Clinical Reasoning:
Recurrence risk is cumulative and medication-independent: After a first episode, recurrence risk is ~50%; after two episodes it jumps to 70%; after three episodes it reaches 90% 1
The fact that he achieved remission without medication does not protect against future episodes—it simply means this particular episode resolved spontaneously, which can occur in MDD
Four months of remission is insufficient: This places him still within the "continuation phase" (typically 4-9 months post-remission), not yet in the maintenance phase where discontinuation could be considered 2
Specific Treatment Algorithm
Step 1: Initiate Antidepressant Now
Start a second-generation antidepressant (SSRI or SNRI) based on:
- Adverse effect profile
- Cost considerations
- Patient preference 2
Preferred agents include: citalopram, escitalopram, sertraline, or venlafaxine 1
Step 2: Duration of Treatment
Minimum 12-24 months of continuous treatment from the point of starting medication (not from his spontaneous remission) 1, 2
The rationale: Guidelines recommend maintenance treatment for recurrent depression should continue for years to lifelong in patients with ≥2 episodes 2. The American Family Physician guideline specifically notes that patients with recurrent depression (defined as ≥3 episodes) who were treated to remission had significantly lower recurrence rates when maintained on antidepressants versus placebo over 24 months 1
Step 3: Monitoring Schedule
- Assess within 1-2 weeks of starting medication for adverse effects and suicidality 2
- Monthly monitoring for the first 6-12 months after achieving stable remission on medication 3
- Use PHQ-9 scores at each visit to track response
- Monitor for: ongoing symptoms, suicide risk, adverse effects, adherence, environmental stressors 3
Critical Pitfalls to Avoid
Do not be misled by the current PHQ-9 of 0: This represents spontaneous remission of the current episode but does nothing to prevent the next episode. The evidence shows that antidepressant medication does not prevent relapse if discontinued at the end of the acute phase 1, meaning protection requires active ongoing treatment.
Do not delay treatment: The greatest risk of relapse occurs in the first 8-12 weeks after discontinuing antidepressants 3. Since he's never been on medication, he has no pharmacologic protection against recurrence.
Do not confuse "never medicated" with "doesn't need medication": The 2015 American Family Physician guideline emphasizes that systematic reviews show continued treatment with antidepressants after remission protects against recurrence and relapse 1. A 1998 study showed patients with continued treatment had much lower relapse rates (1.85% vs 6.24% per month) compared to those who discontinued 4.
Addressing the Nuance of This Case
While recent research (2026) suggests that for very low-risk patients (first mild episode), the medication burden may outweigh benefits 5, your patient explicitly has severe recurrent MDD—placing him in the high-risk category where maintenance clearly provides substantial benefit. The same decision analysis showed that for high-risk recurrent depression, only 1.5 medication-years are needed to prevent one depression-month, making this highly efficient 5.
The 2025 network meta-analysis confirms that all active antidepressant strategies significantly outperformed placebo in relapse prevention (RR 0.54 for continuing same dose) 6, and a 2025 Australian review concluded there are substantial risks of depressive relapse from antidepressant discontinuation 7.
Alternative Consideration
If the patient strongly refuses medication, the only evidence-based alternative is mindfulness-based cognitive therapy (MBCT), which showed equivalent protection to maintenance antidepressants in one trial 8. However, this requires 8 weekly group sessions and is less accessible than pharmacotherapy.